^
Association details:
Biomarker:KRAS mutation
Cancer:Non Small Cell Lung Cancer
Drug:sirolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

Excerpt:
...inhibiting mTOR using rapamycin had a more pronounced affect on proliferation in LKB1/KRAS mutant cell lines; in this case, the sensitive cluster also included the LKB1/BRAF mutant cell line CAL12T. The IC50 of the LKB1/MAPK mutant cluster was significantly different from the control cluster (40 nM vs >100 nM, P⩽0.04)...